Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use

Kuloğlu, Mehmet Murat; Çayköylü, Ali; Ekinci, Okan; Bayındırlı, Deniz; vural, güliz; Denız, Orhan

doi:10.1177/0269881108099962

Cited by 7 publications

(2 citation statements)

References 15 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 19 published cases 27,[77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94] of parkinsonism or worsened Parkinson's disease, associated with SSRI/SNRI treatments compared to the 13 cases discussed in the prior report. 8 Awareness of a potential relationship between serotonergic antidepressants and extrapyramidal reactions increased in the 1980s when case reports of Parkinson's patients receiving fluoxetine treatment for depression experienced worsening of their Parkinson's symptoms.…”

Section: Parkinsonism Casesmentioning

confidence: 99%

Extrapyramidal Reactions Associated With Serotonergic Antidepressants

Hawthorne

Caley

2015

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Section: Parkinsonism Casesmentioning

confidence: 99%

Extrapyramidal Reactions Associated With Serotonergic Antidepressants

Hawthorne

Caley

2015

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…In humans, the substantia nigra has the highest concentration of paroxetine binding sites [3]. Furthermore, a history of central nervous system damage has been suggested as a potential risk factor for SSRI-induced EPS [4].…”

mentioning

confidence: 99%

Paroxetine-Induced Dysarthria in a 42-Year-Old Man with Pathologic Laughing

Park

Cho

2011

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use

Cited by 7 publications

References 15 publications

Extrapyramidal Reactions Associated With Serotonergic Antidepressants

Extrapyramidal Reactions Associated With Serotonergic Antidepressants

Paroxetine-Induced Dysarthria in a 42-Year-Old Man with Pathologic Laughing

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About